Status:
WITHDRAWN
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborating Sponsors:
National Institutes of Health (NIH)
Dana-Farber Cancer Institute
Conditions:
Pancreatic Adenocarcinoma
Eligibility:
All Genders
50-100 years
Brief Summary
The purpose of this study is to test a double screening strategy for pancreatic cancer, based on a model developed using patient medical records. Investigators would also like to test whether adding s...
Detailed Description
This research aims to identify people who have a higher risk of pancreatic cancer than the general population, by testing a double-screening strategy for pancreatic cancer. The purpose is to allow ear...
Eligibility Criteria
Inclusion
- Study population for part 1 of study:
- \-- Inclusion criteria: i) Male and females age \>= 50 years; ii) at least one clinical visit to an outpatient clinic of the HCO, within the last year, before the study start date.
- Study population for part 2 of study:
- i) model-assigned high-risk subjects; ii) Male and females age \>= 50 years; iii) at least one clinical visit to an outpatient clinic of the HCO, within the last year, before the study start date
Exclusion
- Exclusion Criteria for part 1 of study:
- Personal history of PDAC or current PDAC
- Age below 50.
- Exclusion Criteria for part 2 of study
- model-assigned low or intermediate risk subjects
- Personal history of PDAC or current PDAC
- Age below 50.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 3 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05287347
Start Date
January 1 2022
End Date
December 3 2024
Last Update
May 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115